MEDICAL DEVICES HAVING SURFACE MODIFIERS
20180272050 ยท 2018-09-27
Inventors
Cpc classification
A61L29/06
HUMAN NECESSITIES
A61M2205/0238
HUMAN NECESSITIES
A61M2039/0258
HUMAN NECESSITIES
B29C48/09
PERFORMING OPERATIONS; TRANSPORTING
A61L29/06
HUMAN NECESSITIES
A61M1/3659
HUMAN NECESSITIES
B29K2083/00
PERFORMING OPERATIONS; TRANSPORTING
A61M2207/00
HUMAN NECESSITIES
International classification
A61M1/00
HUMAN NECESSITIES
A61M1/36
HUMAN NECESSITIES
Abstract
Improved medical devices having anti-thrombogenic and anti-adherent surface modifiers for improved medical device performance and patient outcomes are provided. In certain embodiments, the medical devices are at least partially manufactured using an admixture of a base polymer and surface modifying fluoropolymer additives. In certain embodiments, the medical devices are vascular access devices, vascular access accessories, peripheral vascular devices, or components of these devices.
Claims
1-11. (canceled)
12. A vascular access device, comprising: a port assembly; a reservoir arranged within the port assembly and configured to receive a fluid from a vascular system, at least a portion of the reservoir lined with an insert.
13. The vascular access device of claim 12, the insert comprising an admixture of a base polymer and a surface modifying fluoropolymer additive.
14. The vascular access device of claim 12, the reservoir fluidly sealed by a septum.
15. The vascular access device of claim 12, the at least a portion comprising a bottom portion and a side portion of the reservoir.
16. The vascular access device of claim 12, the at least a portion comprising a portion of the reservoir bounded by a base housing portion of the port assembly.
17. The vascular access device of claim 12, the reservoir comprising a top portion sealed by a septum and a remaining portion lined by the insert.
18. The vascular access device of claim 12, the insert formed as a floor insert arranged to cover a bottom surface of the reservoir.
19. The vascular access device of claim 18, at least a portion of side-walls of the reservoir not covered by the floor insert comprising an admixture of a base polymer and a surface modifying fluoropolymer additive.
20. The vascular access device of claim 18, the floor insert having a soft durometer to stabilize a needle inserted into the floor insert.
21. The vascular access device of claim 12, the insert comprising an opening arranged to provide fluid communication between the reservoir and an outlet lumen.
22. The vascular access device of claim 12, the insert comprising an integral outlet lumen.
23. The vascular access device of claim 13, the base polymer comprising silicone.
24. The vascular access device of claim 13, the surface modifying fluoropolymer additive comprising a 2-25% by weight ratio of additive to base polymer.
25. The vascular access device of claim 13, the surface modifying fluoropolymer additive is homogenously distributed throughout a surface of the admixture.
26. A vascular access device, comprising: a port assembly; a reservoir arranged within the port assembly and configured to receive a fluid from a vascular system, at least a portion of the reservoir formed of a surface-modifying macromolecule.
27. The vascular access device of claim 26, the surface-modifying macromolecule comprising: i) a non-chain extended central portion of a segmented block copolymer having a molecular weight of less than 2,000 and comprising a total of no more than ten units A and B, wherein A is a urethane containing group; and B is selected from the group consisting of a polyalkylene oxide, polycarbonate, polyester and lactone; and ii) - terminal polyfluoro oligomeric groups.
28. The vascular access device of claim 26, the surface-modifying macromolecule comprising: iii) a non-chain extended central portion of a segmented block copolymer having a molecular weight of less than 5,000 and comprising a total of no more than ten monomelic units A and B, wherein A is a urethane containing group; and B is selected from the group consisting of a polyalkylene oxide, polycarbonate, polyester and lactone; and iv) - terminal polyfluoro oligomeric groups, selected from CF.sub.3(CF.sub.2).sub.pCH.sub.2CH.sub.2, wherein p is 5-9 and CF.sub.3(CF.sub.2).sub.m(CH.sub.2CH.sub.2O).sub.n, wherein n is 1-10 and m is 1-20.
29. A method of manufacturing a vascular access device, comprising: providing a port assembly; arranging a reservoir within the port assembly configured to receive a fluid from a vascular system; lining at least a portion of the reservoir with an insert.
30. The method of claim 29, the insert comprising an admixture of a base polymer and a surface modifying fluoropolymer additive.
31. The method of claim 29, the at least a portion comprising a portion of the reservoir bounded by a base housing portion of the port assembly.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] The foregoing purposes and features, as well as other purposes and features, will become apparent with reference to the description and accompanying figures below, which are included to provide an understanding of the invention and constitute a part of the specification, in which tike numerals represent like elements, and in which;
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040]
[0041]
[0042]
[0043]
[0044]
[0045]
DETAILED DESCRIPTION OF THE INVENTION
[0046] The present invention can be understood more readily by reference to the following detailed description, the examples included therein, and to the Figures and their following description. The drawings, which are not necessarily to scale, depict selected preferred embodiments and are not intended to limit the scope of the invention. The detailed description illustrates by way of example, not by way of limitation, the principles of the invention. The skilled artisan will readily appreciate that the devices and methods described herein are merely examples and that variations can be made without departing from the spirit and scope of the invention. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.
[0047] Referring now in detail to the drawings, in which like reference numerals indicate like parts or elements throughout the several views, in various embodiments, presented herein are improved medical devices having surface modifiers.
[0048] As used herein, additives refer to any materials that are added into the polymeric materials of the present invention to influence physical, mechanical, or other material properties, or to advantageously impact manufacturability or desired performance characteristics. Examples of known additives for polymeric materials include pigments (used synonymously herein with colorants), solvents, biostabilizers, plasticizers, nucleating agents fillers, radiopaque powders (or other forms), and materials in any form that enhance biocompatibility or other in vivo performance characteristics. An example of a fluoropolymer additive that is used in embodiments of the present invention is marketed under the trade name ENDEXO (Interface Biologics, Inc., Toronto, Ontario Canada), which generally refers to a fluoropolymer additive material described in U.S. Pat. No. 6,127,507, which is herein incorporated by reference. As used herein, fluoropolymer means a fluorocarbon-based polymer, including oligomers, having carbon-fluorine bonds. In a preferred embodiment, the fluoropolymer used in the present invention is a fluoroalkyl fluoropolymer that is characterized by terminal polyfluoro oligomeric groups.
[0049] As described in U.S. Pat. No. 6,127,507, this additive may be referred to as a surface modifying molecule or surface modifier. The surface modifying additives, when used in embodiments of the invention, are preferably synthesized in a manner that they contain a base polymer compatible segment and terminal hydrophobic fluorine components which are non-compatible with the base polymer. The compatible segment of the surface modifier is selected to provide an anchor for the surface modifier within the base polymer substrate upon admixture. While not being bound by theory, it is believed that the fluorine tails are responsible in part for carrying the surface modifier to the surface of the admixture, with the chemical resistant fluorine chains exposed out from the surface. The latter process is believed to be driven by the thermodynamic incompatibility of the fluorine tail with the polymer base substrate, as well as the tendency towards establishing a low surface energy at the mixture's surface. When the balance between anchoring and surface migration is achieved, the surface modifier remains stable at the surface of the polymer, while simultaneously altering surface properties. The utility of the additives of the invention versus other known macromolecular additives, lies in 1) the molecular arrangement of the amphipathic segments in the surface modifier chain, i.e. two- fluoro-tails, one at each end, with the polar segment sandwiched between them; 2) the molecular weight of the fluorine tails relative to that of the central segment and; 3) the ability of the materials to inhibit biodegradation of the base polymer when the fluoro-segments are stabilized at the interface, which provides improved blood compatibility and biostability of the base polymers. This latter improvement has not been previously achieved and/or demonstrated with any other family of amphipathic polymeric type surface modifying macromolecules.
[0050] The surface modifying macromolecules used in embodiments of the present invention significantly alter the surface chemistry of, for example, segmented polyurethanes, i.e. the surface modifiers present on the surface of the polymer mixture and exhibit a new hydrophobic surface. This new surface carries many of the attributes of perfluoro-carbon chains and, therefore, is significantly more stable with respect to oxidation and hydrolysis than many polyurethanes. Further, the surface has low fouling properties and low wetting characteristics.
[0051] The surface modifying additives used in embodiments of the present invention are, for example, of use with linear or crossllnked polyurethane-based materials. By tailoring the central segment components of the surface modifier, the fluoropolymer additives can be applied inter alia to a wide range of polymer materials which include polymers synthesized with reagents that are of common knowledge in the field of polyurethanes.
[0052] Referring now to
[0053] Referring to
[0054] The flexible valve element 100 of the present invention is manufactured from an admixture of a base polymer and surface modifying fluoropolymer additives. The fluoropolymer additive is integral to the admixture and homogenously distributed throughout the admixture. A base polymer according to a preferred embodiment is silicone. Desired fluorination levels in the flexible valve element 100 may require a 2-25% by weight ratio of additive to base elastomer. Once the desired levels are achieved, the admixture is rolled into sheets using a calendaring process. A disk shaped element can then be cut using a die, and a slit can be punched into the disk to form the desired slit configuration. Alternative methods known in the art for shaping the disk and cutting one or more slits into the disk can also be employed.
[0055] Since the fluoropolymer additive is distributed homogenously throughout the bulk of the disk, the fluoropolymer additive is present on all valve element body 110 surfaces, including the surface of the interior slit wall 104 and the corner where the interior slit wall meets the face of the valve element body 110. The additional and difficult step of applying an antl-thrombogenic coating to the surface of the interior slit wall 104 can be avoided. The flexible valve element of the present embodiment features superior durability since its anli-thrombogenic properties cannot erode or wear over time, as may otherwise be the case with safety valve having an anti-thrombogenic coating. Since the interior walls of the slit are also anti-adherent, the slit can open uniformly after repeated infusion and aspiration procedures, further minimizing wear and tear of the edges of the slit. Additionally, thromboresistant properties can be incorporated into the internal walls of the valve housing securing the flexible valve element. The flexible valve element 100 can be incorporated into a conventional catheter such as that described in
[0056] Referring to
[0057] Since thrombus will not adhere or buildup on surfaces using these admixtures, catheter infection rates and rates of catheter malfunction due to occlusion can be minimized. For example, using a surface modifier for a 3 French single lumen PICC would allow for a high performance downsized PICC without compromising patient safety associated with thrombus buildup and catheter lumen occlusion. Further, the anti-adherent properties of the inner wall forming the fluid channel reduce the amount of drag on the fluid so that high flow rates can foe maintained. Dual lumen PICC lines could also be further downsized to at least 4 French without compromising performance or patient safety. Single and dual lumen PICC configurations could be even further downsized when able to accommodate the type of treatment being administered. As complication and PICC removal rates decrease, the patient benefits from experiencing less trauma while healthcare costs are minimized.
[0058] Referring to
[0059] The additive is integral and homogenously distributed throughout the introducer shaft and the dilator, and the surface modifier tends to present on all surfaces formed during the extrusion pnocess. As a result, the anti-thrombogenic properties are present both on the inner and outer surfaces of the sheath wail 322, preventing thrombus adhesion both within the sheath lumen 328 and on the outer surface of the sheath wall 322 at the site of vessel entry. Further, these anti-thrombotic properties can be achieved in a simple manufacturing process that does not require a more complicated anti-thrombogenic coating approach. Additionally, the anti-adherent inner surfaces of the introducer sheath 320 lumen 328 facilitate less resistance upon advancement upon introduction of a medical device. The anti-adherent outer surfaces of the introducer sheath assembly help the medical professional achieve a smooth transition into the site of the venipuncture and into the vessel with minimal resistance. Specifically, the outer surface of the sheath wall 322, the outer and leading surfaces of the tapered tip 316 on the dilator 310, and all transition zone 308 surfaces between the dilator 310 and the sheath 320 which slide along the puncture site upon insertion will present with the anti-adherence of the surface modifying fluoropolymer additive, leading to a superior and smooth insertion.
[0060] Referring to
[0061] The reservoir is lined with an insert 420 composed of an admixture of a rigid base polymer and a surface modifying fluoropolymer additive. To provide an anti-thrombogenic property to the insert 420, fluoropolymer additives are combined in admixture with a base polymer for the manufacture of the insert 420. The fluoropolymer additive is integral to the admixture used in manufacturing the insert 420. As a result, when the insert 420 is manufactured through a polymer forming process known in the art, such as injection molding, the fluoropolymer additive integral and homogenously distributed throughout the admixture is present throughout the insert's bulk and on any surfaces. The anti-thrombotic properties of the insert 420 allow for a decreased incidence of sludge. Alternatively, the entire port housing could be manufactured to include a thromboresistant additive by molding the component from a compound mixture to include the additive. Since the reservoir is resistant to platelet adhesion and thrombus buildup due to the additive, the laminar flow within the port is more consistently maximized, increasing flushing ability and providing a synergistic mechanism for keeping the port reservoir clear of sludge. This property helps to optimize port system performance for high flow procedures such as power injection of contrast fluid. Further, the anti-adherent properties of the surface modifying fluoropolymers help to promote a rapid flushing action, which also helps to prevent sludge.
[0062] Another advantage of using an insert is that it has superior durability characteristics compared to an antl-thrombotic coating. Implantable ports are designed for patients with longer term and repeated need for procedures such as power injection of contrast fluid. When infusion needles are inserted into the reservoir, the tip of the needle will commonly contact and scrape the bottom surface. This may happen repeatedly over the lifespan of the port. Power injection of fluid into the reservoir may also tend to facilitate the erosion and wear of a surface coating over time, decreasing the effectiveness of the coating to provide an anti-adherent properly in the reservoir. However, the insert 420 contains the fluoropolymer additive throughout its bulk, and therefore manual abrasion of the insert's surface caused needle scrapes and surface erosion from power injection will not impact anti-thrombotic properties within the reservoir due to the homogenous distribution of the additive throughout the entire thickness of the reservoir insert wall. Alternatively, a floor insert 422 could be customized specifically for covering the bottom surface, which is the area of the reservoir most affected by sludge buildup and scraping from the infusion needle. For ports utilizing a floor insert 422, an anti-thrombotic coating could be used on the side walls of the reservoir. In some embodiments, the floor insert 422 could have a soft durometer so that the tip of an inserted needle can stabilize within the floor insert, providing more control over fluid flow and efficiencies in reservoir fluid dynamics.
[0063] As the port fills with fluid or as blood splashes around the port reservoir, it is possible that certain amounts of blood will come into contact with the bottom surface of the septum. The port septum, typically made from a self-sealing elasiomeric polymer such as silicone, may also comprise a fiurorpolymer additive for providing a top surface to the reservoir that is thromboresistant. As illustrated in
[0064] Port systems described above can be used in conjunction with a port, catheter 430 shown in
[0065] Referring to
[0066] The fluoropolymer additive is integral to the bulk of the cannula wall, and homogenousily distributed throughout the wall of the cannula shaft. As a result, when the cannula 506 is initially fanned, then subsequently cut at its distal end to form pivoting strips 502, anti-adherent properties are present at the edges 512 and surfaces 514 of the strips 502. These anti-adherent edges 512 and surfaces 514 resist thrombus buildup, further facilitating the rapid en bloc removal of clot, emboli, or thrombi from the target site. Since the fluoropolymer additive is homogenously distributed throughout the cannula wall, strips of various shapes can be easily cut and manufactured without the complicated step of evenly distributing an anti-adherent coating or layer on the edges of the strip. The jacket 510 and balloon 508 can aiso.be composed of an admixture of a flexible polymer (such as flexible polymers known in the art for manufacturing medical balloons) and a fluoropolymer additive to facilitate rapid movement of clot, emboli, or thrombi through the funnel 504. This further adds to the anti-fouling advantage of embodiments of the invention, particularly for sections of the cannula 500 that are reliant on moving parts for an effective procedure. Additionally, these features help to maintain a consistent slow rate throughout the cannula and the system during the procedure. As an added benefit, this anti-adherent feature will facilitate less resistive removal of these components from their molds during manufacture.
[0067] Referring to
[0068] Referring to
[0069] This simplified manufacturing technique for providing high performance thromboresistant and anti-adherent medical devices can be applied to numerous medical devices having side holes, for example, thrombolytic catheters, dialysis or drainage catheters. Referring to
[0070] Urinary and drainage catheters of this design will have increased resistance to catheter encrustation or buildup of biofilms, often encountered during long-term urethral catheterization. The integral distribution of the fluopolymer additive in the shaft material provides for a finished product with anti-adherent properties on all surfaces, including the interior walls of the side and end holes, where encrustation and crystallization may tend to form and accumulate on the catheter. The minimization of these occurrences will lead to better device performance, lower infection rates, and lower health care costs as catheter replacement and remediation procedures are minimized. Further, these hard crystalline deposits can traumatize the patent upon catheter removal, and this design will help to minimize that risk of injury to the patient.
[0071] Referring now to
[0072] Referring to
[0073]
[0074] Although not illustrated, the surface modifier contained in each segment may transition more or less abruptly between segments. As an example, the entire proximal segment may contain an additive of 2.5% by weight which abruptly changes to 1.5% for the transition segment and 3.5% for the distal segment. Each segment may be separately extruded and then assembled together using RF welding or other known techniques to produce a monolithic catheter body. Alternatively, TIE extrusion as discussed below may be used to form the unitary shaft body.
[0075] A method of manufacturing a catheter shaft with varying ratios of materials along the length of the catheter shaft been previously described in U.S. Pat. No. 4,883,148 to Dandeneau, incorporated herein by reference. Specifically, the shaft tubing may be extruded using a Total Intermittent Extruded (TIE) process in which a polymer base is mixed with varying amounts of a second, different durometer material before being extruded as a single, unitary tube. The catheter shaft of the current embodiment may be manufactured using the TIE process to achieve the varying ratio of surface modifier to base polymer along the length of the catheter shaft. A method of manufacturing a venous access catheter shaft having customized and variable material characteristics of durometer and radiopaque filler has been previously described in U.S. Pat. No. 7,618,411 to Appling, Incorporated herein by reference.
[0076] Using the techniques described above, a venous access catheter shaft can be manufactured with sufficient surface modifier additive to prevent thrombus accumulation where it is most likely to occur thus maintaining the indwelling performance of the device. As a non-limiting example, the catheter shaft 903 may have higher concentrations of the surface modifier at the distal segment 906 of the shaft with a constant or varying percentage of surface modifier across the transition 905 and proximal 904 segments of the shaft. This design provides a catheter shaft having enhanced blood compatibility to prevent thrombus formation on the catheter tip section and also minimize the formation of a fibrin sheath tail at the distal tip of the catheter. As another non-limiting example, a venous access catheter shaft may be manufactured having sufficient surface modifier additive to prevent thrombus accumulation adjacent to the veno-puncture insertion site of the catheter. With reference back to
[0077] Providing a higher concentration of surface modifier along the distal 908 segment of the catheter shaft provides additional advantages when the distal tip section geometry of the shaft is non-uniform, irregular or non-tubular. For example, a dialysis catheter distal section is often shaped to maximize centering within the vessel and reduce side and end hole occlusions caused by aspiration during dialysis. See, for example
[0078]
[0079] Although not illustrated in
[0080] Accordingly, the radiopaque filler, the surface modifier and the base polymer percentages by weight may be varied to produce customized shaft qualities. As an example, the radiopaque filler may be increased along the transition segment until it reaches approximately 40% filler at the distal segment, the surface modifier may reach 2.5%, and the base polymer 57.5% by weight at the distal end section. The proximal segment may have a decreased amount of radiopaque filler and an increased amount of surface modifiers to produce a proximal shaft segment having both enhanced anti-thrombogenic characteristics and increased stiffness and strength due to the reduced percentage of radiopaque materials relative to polymer base. In general, by varying the urethane durometer, the amount by weight of radiopaque filler and the amount by weight of surface modifier additive, the desired flexural, tensile, radiopacity, thrombo-resistance and fibrin sheath resistance characteristics of the shaft may be customized to meet the specific clinical requirements.
[0081] Varying the concentration of the surface modifier along the catheter shaft also provides benefits associated with use of less surface modifier. The cost of a surface modifier additive is expensive and one way to minimize the costs associated with manufacture of the shaft is to use less overall surface modifier additive per a given length of tubing. As an example, once such benefit is lowered manufacturing costs due to using less overall surface modifier additive per catheter shaft by selectively concentrating the surface modifier where most needed and minimizing it where not needed. In addition, by minimizing the amount of surface modifier in those sections of the catheter shaft where it is least needed, the overall structural integrity and tensile strength of the polymer tube is not compromised.
[0082] In an alternative method of manufacturing the catheter shaft of the present invention, the monolithic tube is formed by joining two or more distinct tubing segments using an RF welding or thermal bonding procedure. This method is particularly advantageous for dialysis catheters with non-uniformly shaped tips, such as those disclosed in U.S. Pat. No. 8,317,773 to Appling et al. The transition and proximal tube segments may be formed from a base polymer and uniform percentage by weight of the surface modifier using a standard extrusion process. The percentage by weight of the surface modifier may range from 0% to 2.5% along the combined proximal/transition tube. The distal segment may be extruded separately and may be formed of a base polymer and surface modifier of a different percentage by weight from the other tubing segment. Typically, the surface modifier loading will be greater in the distal tip segment to provide enhanced platelet resistance at the catheter segment most likely to promote clot formation, as previously discussed. The monolithic tube is then formed by RF welding or thermal bonding the proximal end of the distal segment to the distal end of the proximal segment to create a seamless, unitary shaft. The RF welding or thermal bonding processes may also include forming the tip geometry. The resultant monolithic tube is characterized by a proximal and transition segment having a uniform surface modifier loading across the combined length of the two segments and a distal segment with a greater surface modifier loading with a non-linear tip profile. The distal segment surface loading may be uniform across the segment length or may be varied as previously described.